JP2023141629A - composite fiber - Google Patents

Abstract

To provide a composite fiber having an excellent anti-virus property and durability.SOLUTION: In the composite fiber formed of a thermoplastic polymer A containing an anti-virus component and a thermoplastic polymer B, the thermoplastic polymer A is exposed on a fiber surface, and an abundance of the anti-virus component on the fiber surface is 0.5-5.0%.SELECTED DRAWING: Figure 1

Description

The present invention relates to composite fibers containing antiviral components. Specifically, the present invention relates to a composite fiber that exhibits antiviral properties by exposing antiviral components on the fiber surface and has excellent toughness.

In recent years, changes in lifestyle have led to an increased awareness of cleanliness, and an increasing number of consumers are seeking products with antibacterial, antiviral, and other functions. The same needs apply to fibers, and in response to these needs, fibers having various antibacterial and antiviral functions have been proposed. Generally, antibacterial agents and antiviral agents for synthetic resins are well known, and agents that are effective against target bacteria and viruses are selected and modified as necessary before use.

For example, Patent Document 1 proposes a nylon fiber in which a mixture of cupric oxide particles and cuprous oxide particles is diffused (added) into the fiber as an antibacterial and antiviral agent. . Further, Patent Document 2 discloses that a copper- and titanium-containing composition containing titanium oxide including rutile-type titanium oxide and at least one type of divalent copper compound is fixed to the surface of polyester fiber (knit) as an antiviral agent. Post-processing techniques have been proposed to

JP2012-229424A JP 2018-2597 Publication

However, in the case of the fiber described in Patent Document 1, in which the antiviral component is uniformly dispersed in the fiber, in order to ensure antiviral performance, it is necessary to contain a large amount of the antiviral component, and as a result, the fiber properties deteriorate. However, it is susceptible to tearing and abrasion, and has poor practical durability. In order to ensure durability, it was necessary to reduce the amount of antiviral components, which was contradictory as the antiviral properties were inferior. Since the post-processing technique of surface adhesion described in Patent Document 2 loses its antiviral performance after repeated washing, there is a strong demand for fibers that do not rely on post-processing techniques.

The present invention solves the above problems and provides fibers with excellent antiviral properties and durability.

The present invention employs the following configuration in order to achieve the above object. That is,
(1) In a composite fiber consisting of thermoplastic polymer A and thermoplastic polymer B containing an antiviral component, thermoplastic polymer A is exposed on the fiber surface, and the antiviral component peripheral abundance rate in the cross section of the fiber is 0. .5 to 5.0% composite fiber.
Antiviral component peripheral abundance rate (%) = (fiber peripheral length of thermoplastic polymer A) / (circumferential length of fiber cross section) × (antiviral component content in thermoplastic polymer A)
(2) The content of the antiviral component in the thermoplastic polymer A is 1 to 10% by weight. (1) The composite fiber described in (3) The thermoplastic polymer A containing the antiviral component occupies the cross section of the fiber. The composite fiber according to (1) or (2), wherein the area ratio is 5 to 30%.
(4) The composite fiber according to any one of (1) to (3), wherein the composite fiber has a toughness of 15 to 30.
(5) The composite fiber according to any one of (1) to (4), wherein thermoplastic polymer A and thermoplastic polymer B are polyester or polyamide.

According to the present invention, a composite fiber having excellent antiviral properties and durability can be provided.

FIG. 1 is a schematic diagram showing a composite form of a fiber cross section in a composite fiber. FIG. 2 is an example of a composite die for explaining the method for manufacturing composite fibers of the present invention, and is a front sectional view of the main parts constituting the composite die.

The present invention will be explained in more detail below.

The thermoplastic polymer in the composite fiber of the present invention is not particularly limited as long as it is a fiber-forming thermoplastic polymer. The polymers used for thermoplastic polymer A and thermoplastic polymer B may be the same or different. Polyamides or polyesters are preferred because polymers with poor spinnability have poor processability.

Polyesters include polyethylene terephthalate (PET) in which 80 mol% or more of the repeating units are ethylene terephthalate, polybutylene terephthalate in which 80 mol% or more of the repeating units are butylene terephthalate, and 80 mol% or more of the repeating units are trimethylene terephthalate. Some polytrimethylene terephthalates are preferred, and these include aromatic dicarboxylic acids such as terephthalic acid, isophthalic acid, naphthalene 2,6-dicarboxylic acid, phthalic acid, 5-sodium sulfoisophthalate, fatty acids such as adipic acid, sebacic acid, etc. Group dicarboxylic acids and the like may be copolymerized to the extent that the fiber-forming properties originally possessed by the polyester homopolymer are not impaired. Furthermore, these may contain small amounts of additives, matting agents, and the like.

The polyamide may be one obtained by repeatedly condensing and polymerizing amide bonds, such as nylon 6, nylon 66, nylon 12, nylon 510, nylon 610, or a polyamide containing a small amount of a third component. Furthermore, these may contain small amounts of additives, matting agents, and the like.

The antiviral component in the present invention refers to a component that acts at least on influenza virus and inactivates the virus, according to JIS L1922 (2016) "Antiviral test of textile products".

The cross-sectional form of the composite fiber of the present invention is not limited as long as the thermoplastic polymer A containing an antiviral component (hereinafter referred to as antiviral layer) is exposed on the fiber surface, and can be any of the known Complex forms can be applied.

As illustrated in FIG. 1, a sea-island type or core-sheath type in which an antiviral layer is arranged on the fiber surface can be preferably adopted. In the case of single-component fibers that disperse antiviral components uniformly throughout the fiber, it is necessary to contain a large amount of antiviral components in order to ensure antiviral performance, and as a result, the fiber properties deteriorate and are susceptible to tearing and abrasion. Poor practical durability. Therefore, by exposing the antiviral layer on the fiber surface, the virus inactivation effect can be sufficiently exhibited.

Further, it is preferable that the thermoplastic polymer B does not contain an antiviral component, and the thermoplastic polymer B (hereinafter referred to as a general-purpose polymer layer) maintains fiber properties and provides excellent durability.

The higher the content of the antiviral component in the antiviral layer, and the more the antiviral layer is exposed on the fiber surface, the more antiviral performance can be exhibited, but the strength and abrasion properties of the fiber may decrease, etc. It affects the properties, is susceptible to tearing and abrasion, and has poor practical durability. The lower the content of the antiviral component in the antiviral layer, the lower the proportion of the antiviral layer, and the more the general-purpose polymer layer is exposed on the fiber surface, the higher the strength and abrasion resistance, but the lower the antiviral performance. do. Therefore, by effectively disposing an antiviral layer on the fiber surface at an appropriate ratio, it has been possible to satisfy both antiviral properties and durability.

The peripheral presence rate of the antiviral component in the fiber cross section of the composite fiber of the present invention is 0.5 to 5.0%. Preferably it is 1.0 to 2.0%. The antiviral component peripheral presence rate is determined by photographing a cross section of the fiber, and calculating the fiber peripheral length of the antiviral layer, the exposure ratio of the antiviral layer calculated from the fiber peripheral length, and the product of the antiviral component content rate in the antiviral layer. This is the value calculated by .

By setting the peripheral abundance of the antiviral component within this range, excellent antiviral performance and durability can be obtained. If the peripheral presence rate of the antiviral component is less than 0.5%, the virus inactivation effect becomes unstable and stable antiviral performance cannot be obtained. Further, even if the concentration of the antiviral layer is high, if the layer is thick toward the center and the exposure ratio is small, the peripheral abundance of the antiviral component will be small and the durability will be poor. Even if the peripheral presence rate of the antiviral component exceeds 5.0%, the virus inactivation effect reaches a ceiling, affecting the fiber properties and worsening the durability. The peripheral presence rate of the antiviral component can be set to 0.5 to 5.0% by appropriately adjusting the exposure ratio of the antiviral layer and the content rate of the antiviral component in the antiviral layer.

The content of the antiviral component in the antiviral layer is preferably 1 to 10% by weight. More preferably, it is 2 to 5% by weight. The antiviral component content in the antiviral layer here can be calculated from the antiviral component content of the entire fiber and the area ratio that the antiviral layer occupies in the cross section of the fiber. From the viewpoint of forming a composite cross section, the fluidity of the thermoplastic polymer A deteriorates as the antiviral component content increases, so the antiviral component content is preferably 10% by weight or less.

The area ratio of the antiviral layer to the fiber cross section (hereinafter referred to as composite ratio) is preferably 5 to 30%. More preferably it is 7 to 15%. From the perspective of forming a composite cross-section, composite fibers with an antiviral layer on the fiber surface become unstable when the amount of thermoplastic polymer A discharged is relatively small, although it depends on the number of layers and the content of antiviral components. Therefore, the composite ratio is preferably 5% or more.

The exposure ratio of the antiviral layer to the fiber surface is preferably 0.1 to 1. The exposure ratio of the antiviral layer to the fiber surface is the value (ratio) obtained by dividing the fiber outer circumference length of the antiviral layer by the outer circumference length of the fiber cross section. When the exposure ratio is 1, a core-sheath type composite fiber with a thermoplastic polymer A containing an antiviral component as a sheath component and a general-purpose thermoplastic polymer B containing no antiviral component as a core component (Fig. ). If the exposure ratio is less than 1, the fiber will have a sea-island shape with an antiviral layer on the surface, as illustrated in (a) to (d) in Figure 1, but the arrangement and number of antiviral layers can be determined arbitrarily. be. In order to obtain more stable antiviral performance, uniform arrangement and three or more layers are preferred.

The composite fiber of the present invention preferably contains an antiviral component in an amount of 0.05 to 5% by weight based on the weight of the fiber. More preferably, it is 0.1 to 3% by weight.

The toughness of the composite fiber of the present invention is preferably 15 to 30. More preferably, it is 20-30. By setting it as this range, excellent durability can be obtained.

The strength and elongation of the composite fiber of the present invention may be adjusted as appropriate so that the toughness falls within the above range. For clothing, it is preferable to have a strength of 2.5 cN/dtex or more and an elongation of 30 to 50%, depending on the fineness.

The fineness of the composite fiber of the present invention and the single fiber fineness may be adjusted as appropriate depending on the use. For clothing, the fineness is preferably 5 to 250 dtex, and the single yarn fineness is 5 dtex or less. In recent years, there has been a strong demand for thinner and softer clothing, and thinner multifilament varieties have become mainstream. More preferably, the fineness is 168 dtex or less, and the single yarn fineness is 3 dtex or less. The finer the single yarn, the lower the abrasion resistance and strength of the fiber and the lower the overall durability. Therefore, the composite fiber of the present invention is preferable because it has excellent durability.

As the antiviral component used in the present invention, known antiviral agents can be used. Examples include silver compounds, copper compounds, quaternary ammonium salts, pyridine compounds, and tungsten compounds. The antiviral agent exists as fine solid particles dispersed in the thermoplastic polymer A, and by being uniformly dispersed in the fine particle form, it provides a stable antiviral agent in the longitudinal direction of the fiber. Can provide virus performance.

The antiviral agent in the present invention is preferably a combination of a plurality of metal compounds from the viewpoint of uniform dispersibility in the polymer and imparting antiviral performance.

For example, examples of the first metal compound include titanium oxide, zinc oxide, gallium oxide, chromium oxide, germanium oxide, indium oxide, niobium oxide, tin oxide, antimony oxide, and tantalum oxide, and as the second metal compound, Examples include oxides, halides, and sulfides composed of metals such as silver, copper, ruthenium, and nickel.

In the production of the composite fiber of the present invention, the higher the concentration of the antiviral component in thermoplastic polymer A, the stronger the intermolecular interaction of the antiviral agent, which reduces the fluidity of the polymer during melting and causes melt fracture. This tends to occur and the formability of composite cross sections tends to become unstable.
Therefore, in order to arrange the antiviral layer in the cross-sectional form shown in FIG. 1, for example, it is preferable to adjust the degree of polymerization of the thermoplastic polymer A as appropriate.

In the case of polyester, the intrinsic viscosity (hereinafter referred to as IV) is preferably 0.51 to 0.70. It is preferable that the IV is 0.51 or more because the degree of polymerization is not too low and the composite fiber can achieve sufficient toughness to withstand practical use. On the other hand, if IV is 0.70 or less, melt fracture will not occur, uniform composite fibers will be obtained, and toughness will not be reduced, which is preferable.

In the case of polyamide, the sulfuric acid relative viscosity (hereinafter referred to as ηr) is preferably 2.6 to 3.0. It is preferable that ηr is 2.6 or more, since the degree of polymerization is not too low and the composite fiber can achieve sufficient toughness to withstand practical use. On the other hand, if ηr is 3.0 or less, melt fracture will not occur, uniform composite fibers will be obtained, and toughness will not be reduced, which is preferable.

In order to arrange the anti-virus layer in the cross-sectional form shown in FIG. 1, it is preferable to use a composite cap implemented by the composite cap technology described in, for example, JP-A No. 2011-174215.

Since the antiviral layer contains an antiviral agent at a high concentration relative to the thermoplastic polymer A depending on the antiviral performance, the fluidity of the polymer is reduced when melted. When dispensing thermoplastic polymer A with reduced polymer fluidity, a composite nozzle is used which is configured to repeat dispensing, merging and metering multiple times through a merging groove in which a plurality of distribution holes are drilled. The stability of forming a composite cross section can be dramatically improved, and the antiviral layer can be accurately and evenly distributed.

The composite nozzle shown in FIG. 2 is assembled into a spinning pack in a state in which three types of members, a measuring plate 1, a distribution plate 2, and a discharge plate 3 are laminated from above, and used for spinning.

In the nozzle member illustrated in FIG. 2, a metering plate 1 measures the amount of polymer per each discharge hole 6 and inflows, a distribution plate 2 controls the composite cross section and its cross-sectional shape in the cross section of a single fiber, and a discharge plate 3 plays the role of compressing and discharging the composite polymer flow formed by the distribution plate 2.

Although not shown in order to avoid complicating the explanation of the composite nozzle, as for the member laminated above the measuring plate 1, it is sufficient to use a member with a flow path formed in accordance with the spinning machine and the spinning pack. . By designing the measuring plate 1 in accordance with existing flow path members, existing spinning packs and their members can be used as they are. For this reason, there is no need to dedicate a spinning machine specifically for this spinneret.

Furthermore, in practice, it is preferable to stack a plurality of flow path plates between the flow path and the metering plate or between the metering plate 1 and the distribution plate 2. The purpose of this is to provide a flow path through which the polymer is efficiently transferred in the cross-sectional direction of the spinneret and the single fiber, and to introduce the polymer into the distribution plate 2.

The composite polymer stream discharged from the discharge plate 3 is cooled and solidified according to the conventional melt spinning method, and then an oil agent is applied thereto, and the undrawn yarn is once wound up and then heated and stretched, or the undrawn yarn is once wound up. A composite fiber is obtained using a direct spinning/drawing method in which the fiber is heated and drawn without heating.

Hereinafter, the present invention will be explained in more detail with reference to Examples. In addition, the physical property values in Examples were measured by the method described below.

(1) Fineness (dtex)
It was measured in accordance with JIS L1013 (2010) "Testing Method for Chemical Fiber Filament Yarn" 8.3.1 Positive Fineness (Method A). The official moisture content of polyamide was 4.5%, and the official moisture content of polyester was 0.4%.

(2) Strength, elongation, and toughness Measured according to JIS L1013 (2010) "Chemical fiber filament yarn test method" 8.5 Tensile strength and elongation rate. Toughness was calculated using the following formula.
(Toughness) = (Strength) x (Elongation) ^0.5 .

(3) Intrinsic viscosity (IV)
ηr' in the defining formula is calculated by dissolving 0.8g of the sample in 10mL of O-chlorophenol (OCP) with a purity of 98% or higher, and measuring the relative viscosity ηr' using an Ostwald viscometer at a temperature of 25°C using the following formula. and the intrinsic viscosity (IV) was calculated.
ηr′=η/η0=(t×d)/(t0×d0)
Intrinsic viscosity (IV) = 0.0242ηr'+0.2634
[η: viscosity of polymer solution, η0: viscosity of OCP, t: falling time of solution (seconds), d: density of solution (g/cm ³ ), t0: falling time of OCP (seconds), d0: falling time of OCP Density (g/cm ³ )].

(4) Relative viscosity of sulfuric acid (ηr)
0.25 g of the sample was dissolved in 100 ml of sulfuric acid with a concentration of 98% by mass to give 1 g, and the flow time (T1) at 25° C. was measured using an Ostwald viscometer. Subsequently, the flow time (T2) of only sulfuric acid with a concentration of 98% by mass was measured. The ratio of T1 to T2, ie, T1/T2, was defined as the relative viscosity of sulfuric acid.

(5) Peripheral presence rate of antiviral components A. Fiber Cross Section Photography The cross section of the composite fiber was magnified 100 to 300 times and photographed using a KEYENCE digital microscope (VHX-2000). For one single yarn, the area ratio of the antiviral layer to the fiber cross section, the exposed length of the fiber outer circumference of the antiviral layer (total if there are multiple layers), and the total length of the fiber outer circumference were measured. Five arbitrary single yarns were measured and the average value was taken as the average value.
B. Antiviral component content of the entire fiber The crucible was baked in an electric furnace at 800°C, and after cooling, it was precisely weighed (A1). A bone-dried sample is weighed into this crucible (S), and the sample is carbonized while being heated in an electric furnace. Next, the crucible is baked in an electric furnace at 800° C. until it reaches a constant temperature, and then cooled and precisely weighed (A2). Based on the results measured in this way, the content rate was calculated using the following formula.
Antiviral component content of the entire fiber (weight%) = (A2-A1)/S x 100
C. Exposure ratio of antiviral layer Calculated using the following formula.
Exposure ratio of antiviral layer = (Exposed length of fiber outer circumference of antiviral layer) / (Fiber outer circumference total length)
D. Antiviral component content in thermoplastic polymer A Calculated using the following formula.
Antiviral component content in thermoplastic polymer A = (antiviral component content of the entire fiber) x (area ratio of the antiviral layer to the cross section of the fiber)
E. Antiviral component peripheral presence rate Calculated using the following formula.
Amount of antiviral component present on fiber surface = (exposure ratio of antiviral layer) x (antiviral component content in thermoplastic polymer A).

(6) Antiviral properties Tests were conducted in accordance with JIS L1922 (2016) "Antiviral testing of textile products". The measurement method was Plaque assay. The test virus was evaluated using Influenza A virus: A/Hong Kong/8/68 (H3N2) ATCC VR-1679.
Effective: 3>Antiviral activity value ≧2.0
Sufficient effect: Antiviral activity value ≧3.0.

(7) Durability Measured in accordance with JIS L1096 (2020) "Fabric test method for woven and knitted fabrics".
A. Abrasion strength was evaluated using plain woven fabric according to the E method (Martindale method). The test conditions were a standard abrasion cloth made of polyester and a pressing load of 9 kPa. Judgment was based on the number of times of wear until fluffing occurs. 3000 times or more is ◎, 2000 times or more but less than 3000 times is ○, less than 2000 times is ×, and 2000 times or more (◎, ○) is considered to be a pass.
B. Tear strength was evaluated in the warp direction and the weft direction of the plain fabric according to the D method (pendulum method).
In both the vertical and horizontal directions, 15 cN or more is ◎, 10 cN or more is ○, less than 10 cN is ×, and 10 cN or more (◎, ○) is considered to be a pass.

[Example 1]
As an antiviral agent, titanium oxide (WILMISH (registered trademark) HPS POWDER AC-20, manufactured by DIC Corporation) containing titanium oxide supported by copper oxide (CuO), and as thermoplastic polymer A, IV0. 65 homo-PET polymer (high melting point component, melting point 255° C.), thermoplastic polymer B was a homo-PET polymer (melting point 255° C.) having a titanium oxide content of 0.05% by weight and an IV of 0.65.

Thermoplastic polymer A (10% by weight) containing 3% by weight of an antiviral agent and thermoplastic polymer B (90% by weight) were each melted at 285°C in an extruder and merged in a die to form a composite cross section. The antiviral layer illustrated in FIG. 1(a) was discharged from a spinneret at a spinning temperature of 290° C. so that the antiviral layer illustrated in FIG. 1(a) was exposed at six equal locations on the fiber surface.

As shown in Fig. 2, the spinneret is a spinneret in which three types of members, a measuring plate 1, a distribution plate 2, and a discharge plate 3, are stacked from above, and a fine flow path is formed by laminating a plurality of distribution plates. was used.

The take-off device uses the direct spinning/drawing method (DSD), which performs the entire process from stretching to winding.
The discharged polymer passes through a cooling section and an oil supply section, and is taken up by a take-up roll (first HR) set at a speed of 1,728 m/min and a surface temperature of 85°C, and is continuously rolled at 4,489 m/min without being wound up. The film was drawn around a heat treatment roll (second HR) set at 150°C, and stretched 2.6 times. The tension of the drawn and heat-treated yarn was adjusted using godet rollers (3rd GR, 4th GR) set at speeds of 4549 m/min and 4584 m/min, respectively, and the tension was adjusted to 0.20 cN/dtex at a speed of 4500 m/min. The cheese-like package was wound up to obtain a composite fiber of 84 dtex-36 filament.

The obtained composite fibers were used for the warp and weft to produce a plain woven fabric (warp density: 75 pieces/2.54 cm, weft density: 70 pieces/2.54 cm). Table 1 shows the evaluation results for the composite fibers and fabrics obtained.

[Comparative example 1]
Both thermoplastic polymer A and thermoplastic polymer B were the same as in Example 1, except that homo-PET polymers with an IV of 0.65 and containing 0.3% by weight of the same antiviral agent as in Example 1 were used, and were discharged from a round-hole spinneret. A single-component PET fiber of 84 dtex-36 filaments was obtained by spinning in the same manner as in 1. The evaluation results are shown in Table 1.

[Examples 2-3] [Comparative example 2]
In Examples 2 and 3, the antiviral layer illustrated in Figure 1(b) was exposed at four equal locations on the fiber surface, and in Comparative Example 2, the antiviral layer illustrated in Figure 1(d) was exposed at three locations on the fiber surface. A composite fiber of 84 dtex-36 filament was obtained by spinning in the same manner as in Example 1, except that the antiviral component was exposed in equal proportions and the peripheral abundance ratio of the antiviral component was changed as shown in Table 1. The evaluation results are shown in Table 1.

[Example 4]
A composite fiber of 84 dtex-36 filament was obtained by spinning in the same manner as in Example 1, except that the peripheral abundance of the anti-viral component was changed as shown in Table 1 by changing the arrangement of the anti-viral layer. The evaluation results are shown in Table 1.

[Example 5]
A conjugate fiber of 84 dtex-36 filament was obtained by spinning in the same manner as in Example 1, except that the core-sheath cross-sectional shape illustrated in FIG. 1(e) and the peripheral abundance of the antiviral component were changed as shown in Table 1. The evaluation results are shown in Table 1.

[Comparative example 3]
Implemented except that the peripheral abundance of antiviral components was changed as shown in Table 1 by using thermoplastic polymer A (40% by weight) containing 7% by weight of antiviral agent and thermoplastic polymer B (60% by weight). The yarn was spun in the same manner as in Example 5 to obtain composite fibers. The results are shown in Table 1.

Comparative Example 1, in which the antiviral component was uniformly dispersed in the fiber, had low antiviral activity and toughness, and was inferior in antiviral properties and durability.
Comparative Example 2, in which the amount of antiviral component present on the fiber surface was less than 0.5%, had a low antiviral activity value and insufficient antiviral properties. In addition, the antivirus layer was thick in the fiber center direction, had low toughness, and was inferior in durability.
Comparative Example 3, in which the amount of antiviral component present on the fiber surface exceeded 5%, had a high antiviral activity value, but had low toughness and poor durability.

[Examples 6 to 9] [Comparative example 4]
Composite fibers were obtained by spinning in the same manner as in Example 1, except that the content of the antiviral component in the antiviral layer was changed as shown in Table 2. The results are shown in Table 2.

Comparative Example 4, in which the peripheral abundance of antiviral components was less than 0.5%, had a low antiviral activity value and insufficient antiviral properties.

[Examples 10 to 13]
Composite fibers were obtained by spinning in the same manner as in Example 1, except that the area ratio (composite ratio) of the fiber cross section of the antiviral layer was changed as shown in Table 3. The results are shown in Table 3.

[Examples 14-15]
Composite fibers were obtained by spinning in the same manner as in Example 1, except that the IV of thermoplastic polymer A was changed as shown in Table 4. The results are shown in Table 4.

[Example 16]
As thermoplastic polymer A and thermoplastic polymer B, nylon 6 (Ny6) polymer containing no titanium oxide and having an ηr of 2.7 was used. Thermoplastic polymer A (10% by weight) containing 3% by weight of the same antiviral agent as in Example 1 and thermoplastic polymer B (90% by weight) were each melted at 260°C in an extruder and joined together in a nozzle. The fiber was spun at a spinning temperature of 270° C. and discharged from a spinneret so that the antiviral layer illustrated in FIG. 1(a) was exposed at six equal locations on the fiber surface.

As shown in Fig. 2, the spinneret is a spinneret in which three types of members, a measuring plate 1, a distribution plate 2, and a discharge plate 3, are stacked from above, and a fine flow path is formed by laminating a plurality of distribution plates. was used.

The taking-off device employs the direct spinning/drawing method (DSD), which performs the entire process from stretching to winding, and the discharged polymer passes through a cooling section and an oil supply section before being transferred to a taking-off roll set at a speed of 2408 m/min. The film was taken up, and without being wound up once, it was continuously drawn around a heat treatment roll set at 4094 m/min and 170°C, and stretched 1.7 times. The drawn and heat-treated yarn was wound into a cheese-like package at a speed of 4000 m/min and a tension of 0.20 cN/dtex to obtain a composite fiber of 78 dtex-24 filaments.

The obtained composite fibers were used for the warp and weft to produce a plain woven fabric (warp density: 75 pieces/2.54 cm, weft density: 70 pieces/2.54 cm). Table 4 shows the evaluation results for the obtained composite fibers and woven fabrics.

A: Antiviral layer (thermoplastic polymer A containing antiviral component)
B: General-purpose polymer layer (thermoplastic polymer B)
1: Measuring plate 2: Distribution plate 3: Discharge plate 4: Measuring groove A
5: Measuring groove B
6: Discharge hole

Claims (5)

In a composite fiber composed of thermoplastic polymer A and thermoplastic polymer B containing an antiviral component, thermoplastic polymer A is exposed on the fiber surface, and the antiviral component peripheral presence rate in the cross section of the fiber is 0.5 to 0.5. Composite fiber that is 5.0%.
Antiviral component peripheral abundance rate (%) = (fiber peripheral length of thermoplastic polymer A) / (circumferential length of fiber cross section) × (antiviral component content in thermoplastic polymer A) The composite fiber according to claim 1, wherein the content of the antiviral component in the thermoplastic polymer A is 1 to 10% by weight. The composite fiber according to claim 1 or 2, wherein the area ratio of the thermoplastic polymer A containing an antiviral component to the cross section of the fiber is 5 to 30%. The composite fiber according to any one of claims 1 to 3, wherein the composite fiber has a toughness of 15 to 30. The composite fiber according to any one of claims 1 to 4, wherein thermoplastic polymer A and thermoplastic polymer B are polyester or polyamide.

Images